Glycorex Transplantation AB (NGM:GTAB B) Cyclically Adjusted Revenue per Share: kr0.53 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:GTAB B Glycorex Transplantation AB NGM:GTAB B
58 GF Score
Price kr1.34
GF Value kr1.81
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Glycorex Transplantation AB Cyclically Adjusted Revenue per Share?

Glycorex Transplantation AB NGM:GTAB B -3.61% 58 Cyclically Adjusted Revenue per Share is kr0.53 as of Mar. 2026. GuruFocus rates NGM:GTAB B with a GF Score™ of 58/100 and a GF Value™ of kr1.81 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Glycorex Transplantation AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr0.111. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.53 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Glycorex Transplantation AB's average Cyclically Adjusted Revenue Growth Rate was -1.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Glycorex Transplantation AB was -1.80% per year. The lowest was -1.80% per year. And the median was -1.80% per year.

As of today (2026-08-26), Glycorex Transplantation AB's current stock price is kr1.335. Glycorex Transplantation AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr0.53. Glycorex Transplantation AB's Cyclically Adjusted PS Ratio of today is 2.52.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Glycorex Transplantation AB was 11.05. The lowest was 1.45. And the median was 3.43.


Glycorex Transplantation AB  (NGM:GTAB B) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Glycorex Transplantation AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.335/0.53
=2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Glycorex Transplantation AB was 11.05. The lowest was 1.45. And the median was 3.43.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Glycorex Transplantation AB Cyclically Adjusted Revenue per Share Related Terms


Glycorex Transplantation AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Glycorex Transplantation AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Glycorex Transplantation AB Cyclically Adjusted Revenue per Share Chart

Glycorex Transplantation AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.57 0.57 0.55 0.54

Glycorex Transplantation AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.55 0.54 0.54 0.53

NGM:GTAB B vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Glycorex Transplantation AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Glycorex Transplantation AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Glycorex Transplantation AB's Cyclically Adjusted PS Ratio falls into.


NGM:GTAB B
58GF Score
Glycorex Transplantation AB NGM:GTAB B
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Glycorex Transplantation AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Glycorex Transplantation AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.111/133.5600*133.5600
=0.111

Current CPI (Mar. 2026) = 133.5600.

Glycorex Transplantation AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.105 101.019 0.139
201609 0.102 101.138 0.135
201612 0.148 102.022 0.194
201703 0.123 102.022 0.161
201706 0.106 102.752 0.138
201709 0.106 103.279 0.137
201712 0.107 103.793 0.138
201803 0.147 103.962 0.189
201806 0.107 104.875 0.136
201809 0.098 105.679 0.124
201812 0.144 105.912 0.182
201903 0.150 105.886 0.189
201906 0.106 106.742 0.133
201909 0.146 107.214 0.182
201912 0.115 107.766 0.143
202003 0.105 106.563 0.132
202006 0.044 107.498 0.055
202009 0.118 107.635 0.146
202012 0.099 108.296 0.122
202103 0.067 108.360 0.083
202106 0.108 108.928 0.132
202109 0.116 110.338 0.140
202112 0.092 112.486 0.109
202203 0.093 114.825 0.108
202206 0.151 118.384 0.170
202209 0.118 122.296 0.129
202212 0.127 126.365 0.134
202303 0.095 127.042 0.100
202306 0.123 129.407 0.127
202309 0.083 130.224 0.085
202312 0.104 131.912 0.105
202403 0.109 132.205 0.110
202406 0.124 132.716 0.125
202409 0.101 132.304 0.102
202412 0.142 132.987 0.143
202503 0.125 132.825 0.126
202506 0.137 133.699 0.137
202509 0.122 133.480 0.122
202512 0.119 133.390 0.119
202603 0.111 133.560 0.111

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.53 mean?
Glycorex Transplantation AB (NGM:GTAB B) has a Cyclically Adjusted Revenue per Share of kr0.53 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Glycorex Transplantation AB and its competitors.
Is Glycorex Transplantation AB's Cyclically Adjusted Revenue per Share too high?
Glycorex Transplantation AB's current Cyclically Adjusted Revenue per Share is kr0.53. Overall, Glycorex Transplantation AB has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Glycorex Transplantation AB's Cyclically Adjusted Revenue per Share of kr0.53 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Glycorex Transplantation AB and its competitors. Glycorex Transplantation AB's current Cyclically Adjusted Revenue per Share is kr0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (NGM:GTAB B) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.81, compared to a current price of kr1.34 — trading 26.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr0.53. Glycorex Transplantation AB's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Glycorex Transplantation AB (NGM:GTAB B), the current Cyclically Adjusted Revenue per Share is kr0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Glycorex Transplantation AB (NGM:GTAB B) Overvalued in 2026?

Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued. The current stock price of kr1.34 is trading 26.2% below its estimated GF Value™ of kr1.81. GuruFocus considers Glycorex Transplantation AB to be Modestly Undervalued.

Key valuation signals for NGM:GTAB B:

  • Cyclically Adjusted Revenue per Share: kr0.53
  • GF Value™: kr1.81 vs. price of kr1.34 (26.2% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the NGM:GTAB B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Glycorex Transplantation AB Business Description

Other Exchanges O33:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
58GF Score

Get the complete analysis for NGM:GTAB B

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.34
Price
kr1.81
GF Value